Development of Peptide-Based Vaccines for Cancer

被引：83

作者：

Abd-Aziz, Noraini ^{[1
]}

Poh, Chit Laa ^{[1
]}

机构：

[1] Sunway Univ, Ctr Virus & Vaccine Res CVVR, Sch Med & Life Sci, Subang Jaya 47500, Selangor, Malaysia

来源：

JOURNAL OF ONCOLOGY | 2022年 / 2022卷

关键词：

T-CELL RESPONSES; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE CYCLOPHOSPHAMIDE; COLONY-STIMULATING FACTOR; IMMUNE-RESPONSE; ANTIGEN PRESENTATION; CHECKPOINT BLOCKADE; CATIONIC LIPOSOMES; PROSTATE-CANCER; DENDRITIC CELLS;

D O I：

10.1155/2022/9749363

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peptides cancer vaccines are designed based on the epitope peptides that can elicit humoral and cellular immune responses targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). In order to develop a clinically safe and more effective vaccine for the future, several issues need to be addressed, and these include the selection of optimal antigen targets, adjuvants, and immunization regimens. Another emerging approach involves the use of personalized peptide-based vaccines based on neoantigens to enhance antitumor response. Rationally designed combinatorial therapy is currently being investigated with chemotherapeutic drugs or immune checkpoint inhibitor therapies to improve the efficacy. This review discusses an overview of the development of peptide-based vaccines, the role of adjuvants, and the delivery systems for peptide vaccines as well as combinatorial therapy as potential anticancer strategies.

引用

页数：17

共 152 条

[11]

Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111

[12] BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications [J].

Bae, Jooeun ;

Parayath, Neha ;

Ma, Wenxue ;

Amiji, Mansoor ;

Munshi, Nikhil ;

Anderson, Kenneth C. .

LEUKEMIA, 2020, 34 (01) :210-223

[13] MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100 IS RECOGNIZED BY MELANOMA-DERIVED TUMOR-INFILTRATING LYMPHOCYTES [J].

BAKKER, ABH ;

SCHREURS, MWJ ;

DEBOER, AJ ;

KAWAKAMI, Y ;

ROSENBERG, SA ;

ADEMA, GJ ;

FIGDOR, CG .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :1005-1009

[14] Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer [J].

Balachandran, Vinod P. ;

Luksza, Marta ;

Zhao, Julia N. ;

Makarov, Vladimir ;

Moral, John Alec ;

Remark, Romain ;

Herbst, Brian ;

Askan, Gokce ;

Bhanot, Umesh ;

Senbabaoglu, Yasin ;

Wells, Daniel K. ;

Cary, Charles Ian Ormsby ;

Grbovic-Huezo, Olivera ;

Attiyeh, Marc ;

Medina, Benjamin ;

Zhang, Jennifer ;

Loo, Jennifer ;

Saglimbeni, Joseph ;

Abu-Akeel, Mohsen ;

Zappasodi, Roberta ;

Riaz, Nadeem ;

Smoragiewicz, Martin ;

Kelley, Z. Larkin ;

Basturk, Olca ;

Goenen, Mithat ;

Levine, Arnold J. ;

Allen, Peter J. ;

Fearon, Douglas T. ;

Merad, Miriam ;

Gnjatic, Sacha ;

Iacobuzio-Donahue, Christine A. ;

Wolchok, Jedd D. ;

DeMatteo, Ronald P. ;

Chan, Timothy A. ;

Greenbaum, Benjamin D. ;

Merghoub, Taha ;

Leach, Steven D. .

NATURE, 2017, 551 (7681) :512-+

[15] Advances in the development of personalized neoantigen-based therapeutic cancer vaccines [J].

Blass, Eryn ;

Ott, Patrick A. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (04) :215-229

[16] MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses [J].

Boks, Martine A. ;

Ambrosini, Martino ;

Bruijns, Sven C. ;

Kalay, Hakan ;

van Bloois, Louis ;

Storm, Gert ;

Garcia-Vallejo, Juan J. ;

van Kooyk, Yvette .

JOURNAL OF CONTROLLED RELEASE, 2015, 216 :37-46

[17] Current challenges for cancer vaccine adjuvant development [J].

Bowen, William S. ;

Svrivastava, Abhishek K. ;

Batra, Lalit ;

Barsoumian, Hampartsoum ;

Shirwan, Haval .

EXPERT REVIEW OF VACCINES, 2018, 17 (03) :207-215

[18] Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival [J].

Brown, Scott D. ;

Warren, Rene L. ;

Gibb, Ewan A. ;

Martin, Spencer D. ;

Spinelli, John J. ;

Nelson, Brad H. ;

Holt, Robert A. .

GENOME RESEARCH, 2014, 24 (05) :743-750

[19] Improving T cell responses to modified peptides in tumor vaccines [J].

Buhrman, Jonathan D. ;

Slansky, Jill E. .

IMMUNOLOGIC RESEARCH, 2013, 55 (1-3) :34-47

[20] Augmenting Antitumor T-Cell Responses to Mimotope Vaccination by Boosting with Native Tumor Antigens [J].

Buhrman, Jonathan D. ;

Jordan, Kimberly R. ;

U'Ren, Lance ;

Sprague, Jonathan ;

Kemmler, Charles B. ;

Slansky, Jill E. .

CANCER RESEARCH, 2013, 73 (01) :74-85

← 1 2 3 4 5 6 7 8 9 10 →